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Abstract: Psychosis in the context of multiple sclerosis (MS) has previously been reported 
as a rare occurrence. However, recent epidemiological studies have found prevalence rates of 
psychosis in MS that are two to three times higher than those in the general population. Untreated 
psychosis in patients with MS can adversely impact on adherence to MS medication, levels of 
disability, and quality of life. This retrospective case series describes the spectrum of psychotic 
disorders occurring in association with MS using demographic, clinical, and neuroimaging data. 
In the discussion, we highlight the particular diagnostic and treatment challenges that such 
disorders can pose for clinicians and through our case vignettes provide examples of potential 
interventions for this complex patient population.
Keywords: psychosis, multiple sclerosis, neuropsychiatric, cognitive, schizophrenia-like, 
demyelination
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS) characterized by progressive demyelination. It can affect any part of the CNS 
but has a predilection for the white matter tracts of the cerebral hemispheres, optic 
nerves, brainstem, cerebellum, and spinal cord.1,2
It is the most common cause of neurological disability in young and middle-aged 
adults, with recent UK prevalence estimates of 167 in 100,000 and an annual incidence 
of eight in 100,000.3,4 It is two to three times more common in females than in males 
and has an average age of onset of ~30 years.5 Typically, MS presents with motor 
and sensory symptoms such as limb weakness, visual disturbance, ataxia, bladder and 
bowel dysfunction, and sensory deficits. The majority (85%) of cases of MS have a 
relapsing-remitting (RR) course, two-thirds of which go on to develop a secondary 
progressive (SP) form, and one-third continuing with an RR course that does not result 
in severe disability. The remaining 15% of patients have a primary progressive (PP) 
course with gradual worsening of symptoms over time.6 Neuropsychiatric symptoms 
including mood, cognitive, and behavioral abnormalities occur commonly in MS.7–9 
One study using the neuropsychiatric inventory found that up to 95% of MS patients 
had some form of neuropsychiatric symptoms even at an early stage or mild severity of 
disease. Depression and dysphoria were found most frequently, occurring in ~80% of 
cases; anxiety, agitation, and irritability were found in approximately one-third (33%); 
and euphoria, disinhibition, and psychotic symptoms were found in a significantly 
smaller number of patients (13%).10
Cognitive impairment is common in MS and is said to affect between 30% and 70% 
of patients at some point during the course of the disease.11 A large study by Borghi et al12 
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investigated the presence and significant determinants of 
cognitive impairment in MS patients versus healthy controls 
using the Brief Repeatable Battery (BRB) and found rates 
of 35.6%, where “cognitive impairment” was defined as 
having two or more BRB test scores of at least 1.5 standard 
deviations below the scores of healthy controls. A progres-
sive course of MS, older age, the presence of depression, and 
less time in education were found to be predictors of a more 
severe cognitive profile in MS patients.12 A further study by 
Borghi et al13 followed up patients and healthy controls over 
a 2-year period and found that cognitive abilities typically 
compromised in the early stages of MS (attention, work-
ing memory, speed of information processing, and verbal 
fluency) are also more vulnerable to progression compared 
with healthy controls, suggesting a need to identify effective 
rehabilitation treatments that might counteract this decline 
over time. Previous literature shows that patients with a psy-
chiatric disorder and MS tend to have a more severe course 
of their MS than those without psychiatric morbidity.14,15 
Such neuropsychiatric disorders have been associated with 
decreased adherence to MS treatment and poorer outcomes 
in terms of social and occupational functioning and qual-
ity of life.16–18 A recent study by Berrigan et al19 looked at 
direct and indirect effects of comorbidity on health-related 
quality of life (HRQoL) in a large sample of MS patients 
(n=949) and found that after disability status, depression, 
and, to a lesser extent, anxiety were associated with decreased 
HRQoL. A study by Ostacoli et al20 looked at the prevalence 
and determinants of posttraumatic stress disorder (PTSD) in 
a large sample of patients with MS. Twelve of 232 (5.17%) 
patients fulfilled the diagnostic criteria for PTSD, and two 
main determinants of PTSD were found to be statistically 
significant, high anxiety levels and low education level. Both 
factors are likely to be important in planning psychological 
interventions to improve levels of functioning and quality 
of life for patients with MS.20 
Psychotic features in the context of MS occur rarely but 
are far from insignificant, with reported prevalence rates 
two to three times higher than those found in the general 
population.21 A large epidemiological study by Patten et 
al22 involving 10,000 MS patients in Canada found that 
between 2% and 4% had experienced psychotic symptoms 
and met the criteria for a diagnosis of psychotic disorder 
(including organic and nonorganic psychosis). An associa-
tion between MS and psychosis has also been suggested 
by studies of psychiatric inpatients where the prevalence 
of MS was found to be elevated. Pine et al23 identified 
10 patients with MS out of a total of 2,720 psychiatric 
inpatients (five of whom had psychotic illnesses). Another 
study found that 23 out of 2,783 psychiatric inpatients had 
white matter lesions on magnetic resonance imaging (MRI) 
suggestive of MS (four of these patients had a diagnosis of 
schizophrenia).24
There are rare case reports of neuropsychiatric symptoms, 
particularly cognitive deficits and to a lesser degree psychotic 
phenomena, being the presenting manifestation of MS. 
Assouad et al25 presented 18 cases of “cognitive MS” where 
1) cognitive symptoms were the primary and predominant 
manifestation at disease onset, 2) defined criteria for MS 
diagnosis were met, and 3) alternative causes were excluded. 
A small number of case reports document MS presenting as 
psychosis in the absence of hard neurological signs.26–28
Both affective and schizophrenia-like psychotic syn-
dromes have been reported in MS with a predominance of 
positive psychotic symptoms, most frequently persecutory 
delusions, and a relative absence of negative symptoms 
(as seen in schizophrenia).29–31 Feinstein et al14 compared 
the clinical and MRI characteristics of 10 psychotic patients 
with MS against 10 nonpsychotic controls and found that 
compared to schizophrenia, MS-related psychosis presents 
later (mean age 36 years), there is quicker resolution of 
symptoms (a mean of 5 weeks), fewer relapses (60% had 
only one episode), and better long-term outcomes (90% 
remission). The main neuroimaging finding in this study 
was a higher periventricular lesion load (particularly around 
the temporal horns of the lateral ventricles) in psychotic 
patients.14 A number of other MRI studies offer support for an 
association between temporal lobe, as well as frontotemporal 
and temporoparietal lesions, and psychosis in MS.21,28,32
The exact etiology of psychosis in MS is not known. 
However, the following three postulations have emerged: 
1) psychosis and MS are not separate comorbid disorders but 
are thought to share a common pathophysiological process 
(infectious or immunological);21 2) psychotic symptoms 
occur as a result of regional demyelination;14,32 and 3) psy-
chotic symptoms are caused or exacerbated by medications 
used to treat MS, for example, corticosteroids and beta 
interferon.33–36
The broad purpose of this study is to describe the spec-
trum of psychotic disorders found in association with MS. In 
particular, we are interested in describing the phenomenology 
of such psychosis and exploring the possibility that psychosis 
can be the sole presenting feature of MS. Our secondary 
aims are to further explore the risk factors for psychosis in 
patients with MS and to review the psychopharmacological 
management of such patients.
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Methods
This study is a retrospective case series of patients with a diag-
nosis of psychotic disorder and either 1) a definitive diagnosis 
of MS or 2) MRI evidence of demyelination in the absence 
of neurological symptoms (known as a radiologically isolated 
syndrome [RIS]). Ethical approval for the study was not sought 
in accordance with the Kings College Hospital and Maudsley 
Hospital ethics and clinical governance rules which deem that 
historical case files may be used in an anonymized fashion in 
a clinical report without specific consent being obtained.
A total of 15 patients were included in this study having 
been referred to the Neuropsychiatry Service at Kings College 
Hospital and/or the Maudsley Hospital within the 5-year 
period between 2010 and 2015. The main referral source 
was Kings College Hospital Multiple Sclerosis Service with 
a small number of patients referred from general psychiatric 
services seeking a specialist neuropsy chiatric opinion.
Of this total, 13 patients had a diagnosis of MS confirmed 
by a neurologist with a special interest in MS using revised 
McDonald criteria.37,38 The remaining two patients had MRI 
scans suggestive of demyelination but no hard neurological 
findings on review by a neurologist. Hence, they did not 
meet criteria for a diagnosis of MS and were identified as 
having RISs.
All patients had an International Classification of Diseases, 
10th edition (ICD-10), diagnosis of psychotic disorder, made 
by a psychiatrist during the study period. The term psychotic 
disorder stipulated the presence of delusions and/or halluci-
nations in the absence of delirium, allowing schizophrenia, 
schizophrenia-like, and affective psychosis to be included. 
Patients with mood disturbance or cognitive impairment 
without evidence of psychosis were excluded. The temporal 
relationship between MS onset and onset of first psychotic 
symptoms was deliberately left open so that the bidirectional 
relationship between the two disorders could be explored.
Cognitive impairment was rated as mild, moderate, or 
severe based on cognitive assessment scores. In two-thirds 
of cases, bedside cognitive tests such as the Mini-Mental 
State Examination and the Addenbrooke’s Cognitive Exam-
ination were used. The remaining third (all of whom were 
inpatients on the neuropsychiatric unit) underwent more 
detailed neuropsychological assessment using a battery of 
tests covering the main cognitive domains as follows:
•	 General intellectual ability using the Wechsler Adult 
Intelligence Scale-Fourth Edition and Test of Premorbid 
Functioning;
•	 Memory using the Brain Injury Rehabilitation Trust 
Memory and Information Processing Battery;
•	 Language using the Graded Naming Test, the Letter 
Fluency Test, and the Category Fluency Test, and
•	 Executive function using the Delis–Kaplan Executive 
Function System.
Clinical, demographic, and neuroimaging (MRI) data 
were collected retrospectively from medical and psychiatric 
electronic notes. Demographic data consisted of gender, 
age, age at onset of MS and age at onset of first psychotic 
symptoms. Clinical data included type of MS (PP, SP, or 
RR), neurological symptoms/level of disability, degree of 
cognitive impairment, medical comorbidities, psychotic 
phenomenology, ICD-10 psychiatric diagnosis, past psy-
chiatric history, risk factors for psychosis such as family 
history and illicit drug use and antipsychotic treatment. 
MRI data consisted of the main findings as reported by 
a neuroradiologist. The reports were then reviewed for 
comments relating to 1) evidence of dissemination of 
lesions in time and/or space and 2) evidence of lesions in 
periventricular regions and temporal lobes (as previously 
associated with psychotic symptoms in MS and other neu-
rological disorders).14,28,32
Results
The sample consisted of 15 cases identified over 5 years with 
psychosis and MS or an RIS, which is in keeping with previ-
ously reported low incidence rates of psychosis associated 
with MS (Tables 1 and 2).
Table 1 gives an overview of all demographic and clinical 
characteristics for the 15 cases. Table 2 shows the main MRI 
findings, psychotic features, and psychopharmacological 
treatment for each patient.
Demographic and clinical characteristics
The study sample comprised nine males and six females. 
Of these, 13 patients had a confirmed MS diagnosis and 
two had RISs.
The median age at MS diagnosis in the 13 confirmed cases 
was 33 years (range, 17–50 years). Ten patients had a progres-
sive form of MS and three had RR disease. In keeping with 
this finding, significant neurological disability was observed in 
nearly half of the sample, with seven patients being wheelchair 
bound with a severe degree of bladder and bowel dysfunc-
tion. Eleven patients had evidence of cognitive impairment 
that was assessed as either mild (six cases) or moderate (five 
cases) based on neuropsychological assessment. Eight cases 
had medical comorbidities, six of which had an autoimmune 
or inflammatory basis including diabetes mellitus, hypothy-
roidism, and asthma. None of the cases had a positive family 
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history of MS. The median age of onset of psychotic symptoms 
was 39 years (range, 21–50 years; mean 37 years).
Nine patients (60%) experienced their first psychotic 
episode between 4 and 17 years after being diagnosed with 
MS. Of these, six patients were given the ICD-10 diagnosis 
of F06.2 Organic (schizophrenia-like) delusional disorder, 
and the remaining three were diagnosed with F23.9 Acute 
and transient psychotic episodes, one of which also had a 
diagnosis of F07.0 Organic personality disorder.
In three patients (20%), first psychotic symptoms 
occurred a number of years (range, 7–11 years) before MS 
diagnosis or isolated radiological findings of demyelination, 
and all three had an ICD-10 diagnosis of F20.0 Paranoid 
schizophrenia. One such patient had a diagnosis of chronic 
schizophrenia for a period of 11 years before an MRI scan 
(performed during a psychiatric inpatient admission) showed 
lesions highly suggestive of demyelination in the absence of 
clinical neurological findings.
In the remaining three patients (20%), onset of psychotic 
symptoms and MS diagnosis or MRI findings suggestive of 
demyelination occurred at around the same time-point, that 
is, within 1 year of each other. Of these, one patient presented 
with a predominantly cognitive syndrome and mild neuro-
logical symptoms (increased somnolence and unsteadiness 
of gait) and was eventually diagnosed with F02.8 Dementia 
in other specified diseases and F06.0 Organic hallucinosis. 
One patient was diagnosed with MS within months of being 
discharged from a psychiatric inpatient ward having been 
diagnosed with and treated for F32.3 Severe depressive 
episode with psychotic symptoms. The remaining patient, 
who had a history of schizotypal personality disorder and 
social phobia, was admitted to hospital with first-episode 
psychosis and during this admission had an MRI scan that 
revealed white matter lesions suggestive of demyelination in 
the absence of hard neurological signs and symptoms. During 
a subsequent psychiatric admission, she was diagnosed with 
F20.1 Hebephrenic schizophrenia.
In relation to etiological factors for psychosis in the con-
text of MS, a third (33%) of the patients in our sample had a 
positive family history of psychotic disorder in a first-degree 
relative and a third (33%) were regular users of illicit drugs 
known to be psychotogenic, namely, cannabis. Four patients 
(27%) were taking prescribed medication with established 
or putative psychotogenic properties at the onset of first psy-
chotic symptoms, including steroids (methylprednisolone), 
levodopa, interferon beta, and oro-mucosal cannabinoid spray 
(nabiximols). Seven patients (47%) had a previous history of 
nonpsychotic mental illness including depression, anxiety, 
personality disorder, and substance misuse disorder.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
73
.1
26
.2
16
 o
n 
11
-M
ar
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2017:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
308
Gilberthorpe et al
T
ab
le
 2
 M
ai
n 
M
R
I fi
nd
in
gs
, p
sy
ch
ot
ic
 fe
at
ur
es
, a
nd
 p
sy
ch
op
ha
rm
ac
ol
og
ic
al
 t
re
at
m
en
t 
fo
r 
ea
ch
 p
at
ie
nt
N
o
Se
x
IC
D
-1
0 
di
ag
no
si
s
N
eu
ro
im
ag
in
g 
fi
n
d
in
gs
P
sy
ch
ot
ic
 fe
at
ur
es
 o
n 
M
SE
P
sy
ch
op
ha
rm
ac
ol
og
ic
al
 t
re
at
m
en
t
P
re
vi
ou
s 
an
ti
ps
yc
ho
ti
c 
tr
ea
tm
en
t 
(r
ea
so
n(
s)
  
fo
r 
st
op
pi
ng
)
M
os
t 
re
ce
nt
 a
nd
 e
ffe
ct
iv
e 
tr
ea
tm
en
t 
re
gi
m
e
1
F
F0
6.
2 
O
rg
an
ic
  
(s
ch
iz
op
hr
en
ia
-li
ke
)  
de
lu
si
on
al
 d
is
or
de
r
Fl
or
id
 p
er
iv
en
tr
ic
ul
ar
 h
ig
h 
si
gn
al
 
co
ns
is
te
nt
 w
ith
 lo
ng
-s
ta
nd
in
g 
M
s,
 w
ith
 n
or
m
al
 b
ra
in
st
em
 a
nd
 
ce
re
be
llu
m
Pe
rs
ec
ut
or
y 
de
lu
si
on
s,
 
gr
an
di
os
e 
de
lu
si
on
s,
 d
el
us
io
ns
 
of
 je
al
ou
sy
, d
el
us
io
ns
 o
f 
re
fe
re
nc
e,
 s
ec
on
d-
 a
nd
 t
hi
rd
-
pe
rs
on
 a
ud
ito
ry
 h
al
lu
ci
na
tio
ns
, 
th
ou
gh
t 
in
se
rt
io
n,
 p
as
si
vi
ty
 
ph
en
om
en
a,
 la
ck
 o
f i
ns
ig
ht
r
is
pe
ri
do
ne
 4
 m
g/
da
y,
 
ol
an
za
pi
ne
 2
0 
m
g/
da
y 
(in
ef
fe
ct
iv
e)
C
lo
za
pi
ne
 3
50
 m
g/
da
y,
 a
m
is
ul
pr
id
e 
20
0 
m
g/
da
y,
 la
m
ot
ri
gi
ne
 2
00
 m
g/
da
y,
 
im
ip
ra
m
in
e 
10
0 
m
g/
da
y
2
F
F0
6.
2 
O
rg
an
ic
  
(s
ch
iz
op
hr
en
ia
-li
ke
)  
de
lu
si
on
al
 d
is
or
de
r
H
ig
h 
le
si
on
 lo
ad
 in
 t
em
po
ra
l 
lo
be
s 
so
m
e 
of
 w
hi
ch
 w
er
e 
ac
tiv
e.
 
W
hi
te
 m
at
te
r 
lo
ss
 a
cr
os
s 
fr
on
to
-
pa
ri
et
al
 lo
be
s,
 b
ra
in
 s
te
m
 a
nd
 r
ig
ht
 
ce
re
be
lla
r 
he
m
is
ph
er
e.
 S
ig
ni
fic
an
t 
at
ro
ph
y 
of
 c
or
pu
s 
ca
llo
su
m
Pe
rs
ec
ut
or
y 
de
lu
si
on
s,
 
gr
an
di
os
e 
de
lu
si
on
s,
 d
el
us
io
ns
 
of
 r
ef
er
en
ce
, s
ec
on
d-
 a
nd
 
th
ir
d-
pe
rs
on
 a
ud
ito
ry
 
ha
llu
ci
na
tio
ns
, t
ho
ug
ht
 
in
se
rt
io
n,
 t
ho
ug
ht
 b
ro
ad
ca
st
, 
la
ck
 o
f i
ns
ig
ht
Q
ue
tia
pi
ne
 4
00
 m
g/
da
y 
(in
ef
fe
ct
iv
e)
, o
la
nz
ap
in
e 
20
 m
g/
da
y 
(in
ef
fe
ct
iv
e)
, 
zu
cl
op
en
th
ix
ol
 (o
ra
l) 
40
 m
g/
da
y 
(e
Ps
es
), 
ri
sp
er
id
on
e 
4 
m
g/
da
y 
(n
on
-a
dh
er
en
ce
), 
ar
ip
ip
ra
zo
le
 
20
 m
g/
da
y 
(in
ef
fe
ct
iv
e)
C
lo
za
pi
ne
 2
50
 m
g/
da
y,
 c
ita
lo
pr
am
 
20
 m
g/
da
y
3
M
F0
6.
2 
O
rg
an
ic
  
(s
ch
iz
op
hr
en
ia
-li
ke
)  
de
lu
si
on
al
 d
is
or
de
r
Pa
uc
ity
 o
f d
ee
p 
w
hi
te
 m
at
te
r 
w
ith
 p
ro
m
in
en
t 
la
te
ra
l v
en
tr
ic
le
s.
 
N
um
er
ou
s 
pa
tc
he
s 
of
 T
2 
hi
gh
 s
ig
na
l 
w
ith
in
 t
he
 s
ub
co
rt
ic
al
 d
ee
p 
an
d 
pe
ri
ve
nt
ri
cu
la
r 
w
hi
te
 m
at
te
r 
of
 b
ot
h 
ce
re
br
al
 h
em
is
ph
er
es
. P
ro
m
in
en
t 
ju
xt
ac
or
tic
al
 le
si
on
s 
w
ith
in
 b
ot
h 
fr
on
ta
l l
ob
es
 a
nd
 c
lu
st
er
in
g 
of
 T
2 
hy
pe
ri
nt
en
se
 le
si
on
s 
ad
ja
ce
nt
 t
o 
bo
th
 la
te
ra
l v
en
tr
ic
le
s
Pe
rs
ec
ut
or
y 
de
lu
si
on
s,
 
de
lu
si
on
s 
of
 r
ef
er
en
ce
, s
ec
on
d-
pe
rs
on
 a
ud
ito
ry
 h
al
lu
ci
na
tio
ns
, 
ta
ct
ile
 h
al
lu
ci
na
tio
ns
, 
th
ou
gh
t 
br
oa
dc
as
t, 
pa
ss
iv
ity
 
ph
en
om
en
a,
 la
ck
 o
f i
ns
ig
ht
r
is
pe
ri
da
l d
ep
ot
 in
je
ct
io
n 
37
.5
 m
g 
m
on
th
ly
 (
in
ef
fe
ct
iv
e)
O
la
nz
ap
in
e 
15
 m
g/
da
y
4
M
F0
6.
2 
O
rg
an
ic
  
(s
ch
iz
op
hr
en
ia
-li
ke
)  
de
lu
si
on
al
 d
is
or
de
r
M
ar
ke
d 
lo
ss
 o
f c
er
eb
ra
l w
hi
te
 m
at
te
r 
w
ith
 v
en
tr
ic
ul
ar
 a
nd
 s
ul
ca
l e
nl
ar
ge
m
en
t 
an
d 
th
in
ni
ng
 o
f t
he
 c
or
pu
s 
ca
llo
su
m
. 
ex
te
ns
iv
e 
T2
 s
ig
na
l c
ha
ng
e 
in
 th
e 
ce
re
br
al
 w
hi
te
 m
at
te
r. 
in
vo
lv
em
en
t o
f 
vi
su
al
 tr
ac
ts
 (l
on
g-
ra
ng
e 
co
nn
ec
tio
ns
 
of
 p
os
te
rio
r 
re
gi
on
s)
 m
ay
 e
xp
la
in
 
“C
ha
rle
s 
Bo
nn
et
 s
yn
dr
om
e”
Pe
rs
ec
ut
or
y 
de
lu
si
on
s,
 
de
lu
si
on
s 
of
 r
ef
er
en
ce
, s
ec
on
d-
pe
rs
on
 a
ud
ito
ry
 h
al
lu
ci
na
tio
ns
, 
vi
su
al
 h
al
lu
ci
na
tio
ns
, o
lfa
ct
or
y 
ha
llu
ci
na
tio
ns
, p
as
si
vi
ty
 
ph
en
om
en
a,
 p
ar
tia
l p
re
se
nt
N
il
r
is
pe
ri
do
ne
 1
 m
g/
da
y,
 
ca
rb
am
az
ep
in
e 
40
0 
m
g/
da
y
5
M
F0
6.
2 
O
rg
an
ic
  
(s
ch
iz
op
hr
en
ia
-li
ke
)  
de
lu
si
on
al
 d
is
or
de
r
Pe
ri
ve
nt
ri
cu
la
r 
an
d 
ju
xt
ac
or
tic
al
 
T
2 
hy
pe
ri
nt
en
si
tie
s 
co
ns
is
te
nt
 w
ith
 
de
m
ye
lin
at
io
n
Pe
rs
ec
ut
or
y 
de
lu
si
on
s,
 
gr
an
di
os
e 
de
lu
si
on
s,
 s
om
at
ic
 
de
lu
si
on
s,
 d
el
us
io
ns
 o
f j
ea
lo
us
y,
 
au
di
to
ry
 h
al
lu
ci
na
tio
ns
, 
ta
ct
ile
 h
al
lu
ci
na
tio
ns
, p
as
si
vi
ty
 
ph
en
om
en
a,
 la
ck
 o
f i
ns
ig
ht
r
is
pe
ri
do
ne
 6
 m
g/
da
y 
(in
ef
fe
ct
iv
e)
, a
ri
pi
pr
az
ol
e 
30
 m
g/
da
y 
(in
ef
fe
ct
iv
e)
Q
ue
tia
pi
ne
 6
00
 m
g/
da
y,
 c
ita
lo
pr
am
 
20
 m
g/
da
y
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
73
.1
26
.2
16
 o
n 
11
-M
ar
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2017:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
309
The spectrum of psychosis in Ms
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Neuroimaging findings
Thirteen of 15 cases had MRI scans that along with clinical 
and cerebrospinal fluid (CSF) findings confirmed a diag-
nosis of MS. Serial MRI scans were performed during the 
5-year study period, which demonstrated dissemination of 
demyelinating lesions in time and space. The remaining two 
cases had established psychotic disorders and incidental MRI 
findings suggestive of demyelination in the absence of hard 
neurological symptoms or signs (RISs). Toward the end 
of the study period, Case no 14 presented to hospital with 
vague neurological symptoms including gait unsteadiness 
and was admitted but still no definitive MS diagnosis was 
made. Case no 15 had an initial MRI scan in 2013 during a 
psychiatric inpatient admission, which showed lesions sug-
gestive of demyelination. A repeat MRI performed 1 year 
later showed no new lesions, and following further review 
of the scans by a neuroradiologist, it was concluded that the 
lesions were “slightly more suggestive of a vascular than 
an inflammatory/demyelinating etiology”. Both cases are 
explored further in the “Discussion” section.
With regard to lesion location, 11 of 15 (73%) MRI scans 
showed lesions in the periventricular white matter, which fits 
with the previous finding of Feinstein et al.14 However, unlike 
Feinstein et al,14 we did not calculate a total lesion score for 
each periventricular area (based on the size and number of 
lesions). In our study, four MRI reports (27%) specified 
temporal lobe involvement, either unilateral or bilateral.
Psychopathological features
The most common psychotic symptom experienced by our 
sample was persecutory delusions (13/15; 87%), followed 
by a lack of insight (12/15; 80%), then delusions of refer-
ence (8/15; 53%) and second-person auditory hallucinations 
(8/15; 53%). Third-person auditory hallucinations, grandi-
ose delusions, and passivity phenomena were experienced 
by 4/15 (27%); visual hallucinations, somatic hallucina-
tions, and thought alienation phenomena occurred in three 
patients, while just two patients had thought disorder and 
one patient experienced delusional perception and delusional 
misidentification.
Table 3 shows the frequencies of individual psychotic 
features in the 15 cases.
Treatment and course of psychotic 
disorder
Nine patients (60%) had been treated previously with antip-
sychotics that were discontinued for a variety of reasons, 
most commonly ineffectiveness. Two patients experienced T
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extrapyramidal side effects and three complained of feeling 
oversedated.
Two patients were offered antipsychotic treatment and 
refused it. They were deemed to have capacity to make this 
decision and did not meet criteria for detention in hospital 
under the Mental Health Act (MHA).
Most recent and most effective antipsychotic treatment 
in all cases was with atypical agents. Risperidone was 
used in four patients (27%), olanzapine in three patients 
(20%), quetiapine in two patients (13%), and aripipra-
zole in two patients (13%). The remaining two patients 
(13%) were considered to be “treatment refractory” and 
were treated with clozapine. Case no 1 was prescribed 
clozapine augmentation medication, namely, amisulpride 
and lamotrigine, since clozapine alone did not adequately 
attenuate her symptoms.
Eight patients (53%) required psychiatric inpatient 
admission; six of these admissions were compulsory under 
the MHA and two were voluntary. Four patients (27%) were 
admitted to a specialist neuropsychiatry inpatient unit for 
integrated mental and physical health care. The other four 
admissions were to general acute psychiatric wards with 
outreach visits from the consultant neuropsychiatrist.
One-third of cases (five patients) achieved full remission 
of psychotic symptoms within 6 months, while two-thirds 
(10 patients) seemed to follow a more chronic course with ongo-
ing attenuated psychotic symptoms while on medication.
Table 4 presents a summary of the main demographic, 
clinical, neuroimaging, and treatment findings.
Discussion
Our study findings show that a spectrum of psychotic 
disorders exists in patients with MS and that at least three 
clinically distinct subgroups can be delineated on the basis 
of the temporal relationship between the two conditions. The 
first and largest group consists of patients with a diagnosis 
of MS that predates psychosis by 4 or more years and with 
no previous history of psychosis. The second group consists 
of patients with preexisting psychotic disorders who go on 
to develop MS several years later. A third group consists of 
patients who present with symptoms of MS and psychosis 
Table 3 Frequencies of individual psychotic symptoms
Psychotic symptoms Number  
of patients  
(N=15), n (%)
Persecutory delusions 13 (87)
Lack of insight 12 (80)
Delusions of reference 8 (53)
second-person auditory hallucinations 8 (53)
Third-person auditory hallucinations 4 (27)
Grandiose delusions 4 (27)
Passivity phenomena 4 (27)
Visual hallucinations 3 (20)
somatic hallucinations 3 (20)
Thought alienation (broadcast, insertion, withdrawal) 3 (20)
Table 4 Summary of demographic, clinical, neuroimaging, and treatment findings
Sample characteristics Number of patients 
(N=15)
Male 9 (60)
Confirmed diagnosis of MS 13 (87)
Incidental white matter lesions suggestive of demyelination on MRI (MS not confirmed) 2 (13)
age at Ms onset,a years 33 (17–50)
age at psychosis onset,b years 39 (21–50)
MS diagnosis preceding first psychotic symptoms by 1 year 9 (60)
First psychotic symptoms preceding MS diagnosis or incidental MRI findings by 1 year 3 (20)
Ms and psychosis presenting within 1 year of each other 3 (20)
Progressive form of Ms 10 (67)
Family history of Ms 0 (0)
Family history of psychosis 5 (33)
Medication known to induce psychosis prescribed at time of onset 4 (27)
Psychotogenic illicit drug use at psychosis onset 5 (33)
Past history of mental illness (non-psychotic) 7 (47)
Periventricular lesions present on Mri 11 (73)
Temporal lobe lesions present on Mri 4 (27)
Treated with antipsychotic medication 13 (87)
required psychiatric inpatient admission for treatment of psychosis 8 (53)
remission of psychotic episode within 6 months 5 (33)
Notes: Data represented as median (range) or n (%). aThirteen patients included in this calculation, bmean age at onset of psychosis= 37 years.
Abbreviations: Ms, multiple sclerosis; Mri, magnetic resonance imaging.
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at around the same time, a proportion of which present with 
solely psychiatric manifestations in the absence of hard 
neurological signs and symptoms.
In the following section, we characterize each subgroup 
in turn and discuss one patient from each subgroup in more 
detail as a case vignette.
subgroup 1: Progressive Ms predating the 
onset of first psychotic symptoms
This group was composed of nine patients (60%), seven of 
which were diagnosed with a progressive form of MS and 
had high levels of neurological disability. Of these, six were 
given the ICD-10 diagnosis of organic (schizophrenia-like) 
delusional disorder, characterized by a preponderance of 
positive psychotic features (persecutory delusions, delu-
sions of reference, poor insight, and second- or third-person 
auditory hallucinations) and a relative absence of negative 
symptoms. Two such patients had psychotic syndromes that 
were refractory to standard antipsychotic medication and 
were given clozapine therapy.39,40
Case no 1 is a 44-year-old married White British female in 
receipt of disability benefits after previously being employed 
in the retail sector. She has a past medical history of atopic 
asthma and eczema and was first diagnosed with MS at the 
age of 26. She neither has a family history of MS or psychosis 
and reports never having used illicit substances or suffered 
previous mental illness. At the onset of first psychotic symp-
toms, she was aged 43 years and had progressive MS with 
significant neurological disability (wheelchair bound with 
severe bladder and bowel dysfunction). She had been treated 
with intravenous steroids within the preceding 6 months and 
had been taking nabiximols (Sativex®),41 an oro-mucosal 
cannabinoid preparation for muscular spasticity, on a regular 
basis for several years. The potential for high-dose steroids 
to induce psychotic symptoms is well-documented33–35 and 
the summary of product characteristics for nabiximol lists 
psychotic symptoms including hallucinations, paranoia, and 
delusional perception as uncommon (1/1,000 to 1/100) 
adverse events.41
Her psychiatric presentation was characterized by 
prominent positive psychotic symptoms, namely, persecu-
tory delusions (eg, neighbors stealing her property, being 
poisoned by doctors, her husband having multiple affairs, 
and being filmed by hidden cameras), grandiose delusions 
(eg, possessing special powers as a clairvoyant and sharing 
close relationships with various celebrities), and second-
person auditory hallucinations of a commanding nature as 
well as marked lack of insight (Figure 1).
Following two admissions to general adult psychiatry 
wards, she was transferred to a specialist neuropsychiatry 
unit where she was initially detained under Section 2 then 
Section 3 of the MHA. Her previous antipsychotic treatment 
consisted of risperidone 4 mg daily followed by olanzapine 
20 mg daily. With both agents proving ineffective, clozapine 
therapy was commenced, slowly titrated up to 350 mg 
daily and augmented with amisulpride 100 mg twice daily. 
During her 9-month admission, she also exhibited marked 
emotional lability with intermittent periods of irritability 
and depressed mood. To treat her affective symptoms, 
lamotrigine 200 mg daily was added and amitriptyline was 
switched to imipramine (100 mg daily).
Based on the putative inflammatory basis of her psychotic 
illness and its use as an adjunctive therapy in treatment-
resistant schizophrenia, high-dose aspirin (600 mg daily) 
was added to her treatment regime.42 Although her psychotic 
symptoms persisted in attenuated form at discharge, it was 
felt that the aforementioned medication regime in combi-
nation with the therapeutic milieu of the neuropsychiatric 
unit lessened the patient’s distress and the impact on her 
interpersonal functioning. The patient was discharged to 
a residential neurorehabilitation center with input from a 
visiting neuropsychiatrist as well as being followed up by 
her previous Community Mental Health Team.
subgroup 2: First psychotic symptoms 
predating diagnosis of Ms or ris
The second group consists of three patients, all with an 
ICD-10 diagnosis of paranoid schizophrenia several years 
before they were diagnosed with MS (and in one case an RIS). 
In this group, the latency period between onset of first psy-
chotic symptoms and either MS diagnosis or an RIS ranged 
from 7 to 12 years. Two of these patients had an established 
Figure 1 Brain Mri of Case no 1.
Notes: (A) axial FLair and (B) sagittal T2 images show confluent T2 hyperintensity 
in the periventricular cerebral white matter with mild generalized brain volume loss.
Abbreviations: MRI, magnetic resonance imaging; FLAIR, fluid-attenuated inversion 
recovery.
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diagnosis of MS at the time they were referred for inclusion in 
this study. The remaining patient did not have an established 
MS diagnosis and was still under investigation by neurolo-
gists at the time he was referred to one of the authors (AD) 
for a neuropsychiatric opinion.
Case no 14 is a single, unemployed 46-year-old African-
Caribbean male with a diagnosis of paranoid schizophrenia 
since the age of 34 and multiple previous psychiatric inpatient 
admissions, mostly involuntarily under the MHA. He has a 
positive family history of psychosis in his father and denies 
misuse of illicit substances including cannabis. His current 
treatment for schizophrenia is olanzapine 30 mg daily, and 
he reports adhering to this consistently. He was previously 
trialed on clozapine medication, but this was discontinued 
due to suspected clozapine-induced myocarditis. He has a 
past medical history of right lung lobectomy for a benign 
carcinoid tumor and no family history of MS. His symp-
toms of schizophrenia over the previous 12 years have been 
predominantly positive, namely, auditory and visual hal-
lucinations and bizarre somatic experiences, with a relative 
absence of negative symptoms.
An MRI brain scan was performed in May 2015 during 
a psychiatric inpatient admission because of subacute cogni-
tive changes including confusion, disorientation, and mild 
deficits in short-term memory “to rule out an underlying 
organic cause”. The scan was reported as showing “multiple 
T2 hyperintense lesions in keeping with demyelination” 
and triggered a referral to neurology. A neurologist per-
formed clinical examination in July 2015 at which time “no 
focal (neurological) abnormalities” were noted. A second 
neurological assessment was carried out in October 2015 
by a different neurologist with expertise in MS and was 
reported as “normal, bar slightly reduced lower leg reflexes, 
slightly slower finger–nose testing, and slight unsteadiness 
on heel–toe walking”. At this stage, the diagnosis given was 
of “an RIS”, and the plan was for a repeat MRI scan and 
further clinical review in 6 months to look for evidence of 
dissemination in time and space.
At assessment in neuropsychiatry outpatient clinic in 
early January 2016, Case no 14 reported experiencing a 
range of somatic symptoms on a daily basis since his diag-
nosis of schizophrenia in 2003 but was clear that these had 
become more intense and distressing in the previous year. 
During this consultation, his experiences were described as 
“beginning with voices” saying things such as “we’re going 
to pull your eyes down your body” or “we’ll take it out” 
followed by somatic experiences lasting several minutes 
before spontaneously resolving. These somatic experiences 
include visual disturbances described as his eyes feeling 
“like they’re fading, getting weak, light, like the substance 
has come out of them” or a sensation of weakness in both 
legs “like the nourishment is sucked out”. In addition, the 
patient described a particularly distressing experience that 
had occurred 2 weeks before: “Something came out of my 
sides like a stabilizer. I felt like I was going out of my frame. 
By frame I mean body. I felt like my spirit came out. I was 
sinking in my frame.”
In mid-January 2016 (2 months before his scheduled 
follow-up with neurology), Case no 14 presented to the 
Accident and Emergency department with a 24-hour history 
of worsening “unsteadiness” and “not feeling himself due to 
nausea, lethargy, and weak legs”. At this time, a repeat MRI 
scan was performed that showed “a new demyelinating lesion 
in the right periventricular white matter, abutting the trigone”. 
During his brief hospitalization, the same neurologist who had 
seen him in October 2015 reviewed him. After looking at his 
latest MRI scans, it was concluded that he should not be given 
steroids or further investigated for MS at this juncture.
At the time of writing, Case no 14 had been seen on one 
further occasion in outpatient clinic by the same neurologist 
following another attendance at A&E with an “out-of-body, 
detached sensation”. At this review, the patient once again 
described feeling “as if his life has been sucked out of his 
head and that he may die”. The clinical impression following 
this review was that these unusual somatic experiences were 
not suggestive of demyelination and were more likely to 
relate to the patient’s psychosis. In the absence of neurologi-
cal symptoms, a diagnosis of MS was not made and a lumbar 
puncture was not performed. He received a diagnosis of an 
RIS with a medical plan to be reviewed again in neurology 
outpatient clinic in a further 6 months (Figure 2).
The term RIS was first used by Moore and Okuda43 to 
describe patients with no obvious past or present neurological 
symptoms indicative of MS, normal neurological examina-
tion, and evidence of white matter lesions on MRI scan 
that fulfill the radiological criteria for MS. The clinical and 
prognostic implications of such lesions in patients with RIS 
continue to be debated, yet existing evidence suggests that 
patients with RIS are at higher risk of developing MS over 
time with two-thirds showing radiological progression and 
one-third developing clinical neurological symptoms after 
5 years of follow-up.44,45
A study by Lubman et al46 investigating incidental MRI 
abnormalities in both healthy controls and patients with psy-
chotic disorders found an increased prevalence of incidental 
brain abnormalities in patients with chronic schizophrenia 
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Figure 2 Brain Mri of Case no 14.
Notes: (A) axial FLair image shows a low lesion load. Lesions are shown in periventricular (arrow) and juxtacortical locations (block arrow). (B) sagittal T2 image shows 
lesions along the callososeptal interface (arrows). (C) axial T2 image shows infratentorial lesions in the left hemipons.
Abbreviations: MRI, magnetic resonance imaging; FLAIR, fluid-attenuated inversion recovery.
when compared to controls and patients with first-episode 
psychosis. The most commonly reported abnormal findings 
across the study (in all three groups) were of white matter 
abnormalities and hippocampal abnormalities. From a total 
sample of 340 patients, 90 patients had chronic schizophrenia 
and 23.3% of these were found to have MRI white matter 
hyperintensities (WMHs) compared to 11.3% of healthy 
controls and 6.5% of patients with first-episode psychosis. 
While a majority of white matter abnormalities were simply 
reported as “WMHs”, five subjects were reported to have 
“possible white matter demyelination”, of which one was 
given a definitive diagnosis of MS and another who was 
initially extensively investigated by neurologists, and not 
diagnosed with MS, but then admitted to a neurology unit 
with optic neuritis 2 years later.
This study offers two explanations for its main finding that 
there is a higher prevalence of incidental brain abnormalities in 
patients with chronic schizophrenia. The first is that the higher 
incidence of brain abnormalities reflects underlying pathol-
ogy related to the illness process. The second is that chronic 
schizophrenia patients may be less likely to report or be inves-
tigated for underlying CNS pathology such as demyelination 
because it is masked by their psychiatric illness. The chal-
lenges of making a definitive diagnosis of MS and the potential 
for diagnostic overshadowing in patients with long-standing 
psychotic disorders are highlighted by Case no 14. Keeping 
such complex patients under regular neurology follow-up (as 
with Case no 14) is likely to minimize unnecessary delays in 
confirming diagnosis and commencing appropriate treatment 
if and when neurological symptoms arise.
While the occurrence of psychopathological features in 
MS is well described, the presence of exclusively psychiatric 
symptoms is not generally considered to be indicative of 
MS and for this reason is often not further investigated. 
Kohler et al26 described two cases of MS presenting as 
chronic atypical psychosis, one in which the diagnosis of MS 
was confirmed at autopsy and another with MRI white matter 
lesions and CSF positive for oligoclonal bands.
subgroup 3: First psychotic symptoms 
and Ms or ris occurring within 1 year 
of each other
The third group also consists of three patients, all of whom 
experienced first psychotic symptoms and were diagnosed 
with MS within the same 1-year period. One such patient 
was admitted to a psychiatric ward where he was diagnosed 
with a severe depressive episode with psychotic features 
and within months of this began to experience gait ataxia, 
dysarthria, and tremor. An MRI scan showed evidence of 
dissemination in space and along with the presence of CSF 
oligoclonal bands confirmed the diagnosis of MS.
One patient with a previous diagnosis of schizotypal 
personality disorder, autistic spectrum disorder (ASD), and 
social phobia was admitted involuntarily to a psychiatric 
ward in 2013 following a deterioration in her mental state 
characterized by somatic delusions, disorganized thinking and 
lack of insight. She was initially diagnosed with an acute 
and transient psychotic episode in the context of schizotypy 
and ASD and treated with antipsychotic medication. During 
the admission, she had an MRI brain scan, which showed 
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“T2 hyperintensities bilaterally with some periventricular 
lesions but predominance within the deep and subcortical 
white matter”. She was subsequently seen by a neurologist 
with expertise in MS, who found no hard neurological signs 
on examination. Evoked visual potentials were performed and 
found to be normal and she was offered but declined a lumbar 
puncture. The MRI findings were reviewed by a neuroradiolo-
gist who felt that on balance the white matter lesions, although 
nonspecific in distribution, were “slightly more suggestive 
of a vascular than a demyelinating etiology” based on their 
location. She was followed up with an MRI scan ~1 year later 
in 2014, which did not show any new lesions. During a further 
psychiatric admission, again under the MHA in November 
2015, she was diagnosed with hebephrenic schizophrenia 
and treated with risperidone 3 mg daily. At the time of writ-
ing, she had not developed any neurological symptoms; her 
MRI findings remain unexplained and essentially incidental 
without overt clinical implications.
Case no 7 is a 50-year-old Nigerian male who worked in 
IT but was forced to stop this due to excessive daytime som-
nolence at the end of 2013. His only past medical history is 
osteoarthritis of the knee. He does not have a family history of 
MS and has never used illicit drugs. His initial presentation was 
in October 2013 to his general practitioner (GP) with the vague 
complaints of “difficulty walking” and “increasing fatigue”. 
One month later, he was seen again by his GP at which time 
he was noted to have cognitive problems including inatten-
tion and memory deficits and was referred to a memory clinic 
for further assessment. By January 2014, his condition had 
deteriorated considerably and he had become more confused, 
was confabulating, and reported both visual and auditory 
hallucinations. As a result, he was referred to a neurologist in 
March 2014 at which time it was noted that he was “generally 
slow with nystagmus on upward-gaze” but pain secondary 
to osteoarthritis had limited more thorough examination. 
An MRI brain scan performed at this time showed “multiple 
WMHs of both cerebral hemispheres, predominantly in the 
periventricular and juxtacortical regions” as well as “severe 
corpus callosum involvement and thinning, moderate diffuse 
volume loss and mild-to-moderate asymmetric right medial 
temporal lobe volume loss” (Figure 3). A diagnosis of chronic 
demyelination was made, and MS was later confirmed by the 
presence of oligocloncal bands in the CSF.
In September 2014, Case no 7 was reviewed in neuropsy-
chiatry outpatient clinic by AD and found to have a psychotic 
disorder characterized by a predominance of hallucinatory 
symptoms including visual and auditory hallucinations. 
He reported hearing multiple voices of a derogatory and 
command nature instructing him to hurt himself, for example, 
“walk in that river” or “use that knife” as well as seeing “white 
images moving across the room”. He also had a prominent 
affective component to his presentation reporting low mood, 
reduced appetite, anergia and amotivation, and suicidal 
ideation. These symptoms apparently first emerged following 
significant life events, namely, losing his job and separating 
from his wife but had worsened considerably since the onset 
of his distressing psychotic symptoms. In terms of manage-
ment, he was commenced on a combination of aripiprazole 
5 mg daily and escitalopram 10 mg daily and later admitted to 
the specialist neuropsychiatry ward for further assessment.
On admission to the neuropsychiatry unit in October 2014, 
Case no 7 presented with psychomotor retardation, flattened 
Figure 3 Brain Mri of Case no 7.
Notes: (A) axial T2 and (B) coronal FLAIR images show confluent lesions in the anterior temporal white matter bilaterally (arrows). Some right hippocampal volume loss 
is also noted (block arrow). (C) axial T2 image shows periventricular (arrows) and juxtacortical lesions (block arrows) with some volume loss.
Abbreviations: MRI, magnetic resonance imaging; FLAIR, fluid-attenuated inversion recovery.
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affect, and poverty speech as well as persistent auditory and 
visual hallucinations as described earlier. His walking was 
unsteady, and he had been prone to poor balance and falls. 
He also had urinary and fecal urgency with occasional incon-
tinence. Neuropsychological evaluation revealed widespread 
cognitive impairment compared to premorbid levels with 
specific deficits in episodic memory. However, part of the 
assessment suggested a significant motivational component 
contributing to his poor test performance and likely leading to 
an overestimate of cognitive impairment. Physical examination 
revealed a “simian gait, abnormal eye movements, slowness of 
upper limb movements, and bilateral clonus”. An electroen-
cephalogram (EEG) was also performed during the admission 
that showed “frequent sharp waves and spike and wave dis-
charges over the frontotemporal region as well as one electrical 
seizure originating from the right temporal region and bursts of 
theta activity over the frontal regions bilaterally and indepen-
dently”. The EEG findings were felt to be suggestive of focal 
epilepsy arising from the right frontal lobe. It was concluded by 
the neurologists that this man’s MRI findings along with CSF 
results were indicative of PP MS with evidence of advanced 
demyelination.
With a short history of less severe neurological symptoms 
and a predominance of cognitive and psychotic symptoms 
at first presentation, Case no 7 fits the description of the 
“cognitive” or “cortical” variant of MS characterized by 
Assouad et al25 who refer to such cases as representing a 
diagnostic challenge and highlight that clinical presenta-
tion may include some or all of the following features: 
“1) a disease onset with cognitive or behavioral change with 
a subsequent severe cognitive impairment occurring early 
in the disease course; 2) a frequent association with other 
psychiatric manifestations, pseudobulbar affect, urinary 
incontinence, and gait disturbance suggestive of high-level 
gait disorder (gait apraxia); 3) infrequent visual, motor, 
sensory, or cerebellar abnormalities that are mild or only 
transiently observed during superimposed relapses; and 4) 
extensive white matter lesions together with rapidly progress-
ing brain atrophy on MRI”.
At onset, Case no 7 had memory loss and depressed mood 
that tally with the findings of a previous study that these 
are the more common symptoms at onset in patients with 
predominantly cognitive MS. Finally, the MRI findings of 
“severe corpus callosum thinning, moderate diffuse volume 
loss, and mild-to-moderate asymmetric right medial temporal 
lobe volume loss” found in Case no 7 correlates with the 
observation of severe atrophy measured as “an increase in 
third ventricular width compared to age-matched healthy 
controls” in the study of Assouad et al.25
In summary, a number of important observations can be 
made from our study data, some of which warrant further 
exploration in future research.
First, our study found a later age of onset of psychosis 
in MS (mean age of 37 years) compared to the general 
population (median age of 22 or 23 years at first presentation 
in patients with schizophrenia47,48), which is consistent with 
previous work by Feinstein et al,14 who found a mean age of 
onset of psychosis in MS of 36.6 years.
Second, in our sample, there was a preponderance of 
males with MS and psychotic disorders compared to females 
(9 males:6 females). This fits with a previous finding by 
Davison et al49 who found 21 of 39 cases of psychosis in MS 
to be male. Interestingly, however, this gender difference is 
at odds with the 2:1 female-to-male ratio found in MS and 
the roughly equal gender rates for schizophrenia in the gen-
eral population.50 It is worth noting that the large Canadian 
study by Patten et al22 did not find a gender difference in 
co-occurring MS and psychosis.
Third, our sample has a high percentage (73%) of 
patients with cognitive impairment (rated as either mild or 
moderate but not severe). All patients in the study assessed 
as having “moderate” cognitive impairment had a progressive 
form of MS and a secondary (organic) psychotic disorder. 
These findings are in keeping with previous evidence of high 
levels of cognitive impairment in MS and the more specific 
finding of Borghi et al12,13 that patients with progressive MS 
and neuropsychiatric comorbidity such as depression are likely 
to have lower cognitive assessment scores. 
Lastly, in the sample, the majority of patients had neuro-
logical symptoms several years before the onset of psychosis 
(60%), and in this subgroup, it was more likely that 1) the 
patient had a progressive form of MS with high levels of 
neurological disability; 2) the patient’s ICD-10 diagnosis was 
organic schizophrenia-like disorder (characterized exclusively 
by positive psychotic symptoms); 3) the patient had cognitive 
impairment; and 4) the MRI showed evidence of significant 
brain demyelination using terms such as “florid”, “extensive”, 
and “numerous” to describe hyperintense lesions most often in 
periventricular areas. Furthermore, most patients in this sub-
group had at least one premorbid vulnerability factor (family 
history, psychotogenic drug use, and premorbid psychiatric 
history) for developing psychosis. Such a group has been 
described in previous studies and adds further support to the 
hypothesis that demyelination superimposed on premorbid 
vulnerability factors is responsible for the association of MS 
and psychosis.7,8
Of particular interest in this study are the outlying 
cases where psychosis predates the onset of MS or an 
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RIS by several years and the demyelination hypothesis 
is less obviously applicable. Such cases (nos 11, 12, 
14) raise the possibility of an alternative explanation 
for the association of MS and psychosis such as shared 
pathogenesis. For example, exposure to a virus at a 
critical developmental stage (in utero, at birth, or dur-
ing childhood) as per the neurodevelopmental model of 
schizophrenia.51 One of the authors (KO’C) of our study 
has also written a review article about immune factors in 
schizophrenia.52 The two patients in this study with RISs 
continue to be followed up in neuropsychiatry and neurol-
ogy outpatient clinics.
Limitations
Our study has a number of limitations, not least its small 
sample size, and would benefit from further large-scale epi-
demiological studies looking at the prevalence of psychosis 
in the context of MS along with focused neurobiological 
research investigating the putative inflammatory and immu-
nological etiology of psychosis. First, as a retrospective 
case series, this study made use of the results of previously 
performed cognitive assessments and therefore did not use 
the same cognitive assessment method for each patient. It 
follows that this study would have benefited from having all 
patients assessed using the same assessment tool, for exam-
ple, the BRB, which is a validated assessment tool with good 
sensitivity as a measure of cognitive dysfunction in MS.53 
Second, this study may have benefited from further analysis 
of education level, as in other studies of neuropsychiatric 
disorders in MS since this may have revealed itself to be an 
important risk/protective factor for psychosis in MS. Finally, 
we concede that the neuroimaging analysis was basic and 
descriptive. Future research might aim to add to the work 
done by Feinstein et al14 by using more detailed volumetric 
neuroimaging methods such as voxel-based morphometry to 
better elucidate any differences between the brains of MS 
patients with and without psychosis.
Conclusion
Psychosis in MS is a relatively uncommon neuropsychiat-
ric presentation when compared to the burden of affective 
disorders and cognitive impairment in MS. Nevertheless, 
it has a significant additional impact on social and occupa-
tional functioning and quality of life. Furthermore, untreated 
psychosis can adversely affect a patients’ adherence to their 
MS treatment regime and thus give rise to worse neurologi-
cal outcomes.
Our study further characterizes the spectrum of psychotic 
disorders in MS and in doing so highlights some of the 
particular diagnostic and therapeutic challenges that such 
disorders can pose for neurologists and psychiatrists alike. 
By describing the relative efficacy and common side effects 
of the psychopharmacological medication regimes used in 
our patients, we provide examples of potential interventions 
for this complex patient population. Further antipsychotic 
trials in patients with psychosis in MS are required to advance 
existing descriptive studies and establish a more robust 
evidence base to guide treatment choices.
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